The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients
Open accessAbstract
Resistance mutations to hepatitis C virus (HCV) nonstructural protein 3 (NS3) protease inhibitors in <1% of the viral quasispecies may still allow >1000-fold viral load reductions upon treatment, consistent with their reported reduced replicative fitness in vitro . Recently, however, an R155K protease mutation was reported as the dominant quasispecies in a treatment-naïve individual, raising concerns about possible full drug resistance. To investigate the prevalence of dominant resistance mutations against specifically targeted antiviral therapy for HCV (STAT-C) in the population, we analyzed HCV genome sequences from 507 treatment-naïve patients infected with HCV genotype 1 from the United States, Germany, and Switzerland. Phylogenetic sequence analysis and viral load data were used to identify the possible spread of replication-competent, drug-resistant viral strains in the population and to infer the consequences of these mutations upon viral replication in vivo . Mutations described to confer resistance to the protease inhibitors Telaprevir, BILN2061, ITMN-191, SCH6 and Boceprevir; the NS5B polymerase inhibitor AG-021541; and to the NS4A antagonist ACH-806 were observed mostly as sporadic, unrelated cases, at frequencies between 0.3% and 2.8% in the population, including two patients with possible multidrug resistance. Collectively, however, 8.6% of the patients infected with genotype 1a and 1.4% of those infected with genotype 1b carried at least one dominant resistance mutation. Viral loads were high in the majority of these patients, suggesting that drug-resistant viral strains might achieve replication levels comparable to nonresistant viruses in vivo . Conclusion: Naturally occurring dominant STAT-C resistance mutations are common in treatment-naïve patients infected with HCV genotype 1. Their influence on treatment outcome should further be characterized to evaluate possible benefits of drug resistance testing for individual tailoring of drug combinations when treatment options are limited due to previous nonresponse to peginterferon and ribavirin. (Hepatology 2008;48:1769–1778.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thompson, J. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.24.4876 · Cited by 38,993
Lauer, G. M., & Walker, B. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107053450107 · Cited by 2,973
Self-citationHadziyannis, S. J., Sette, H., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Bernstein, D., Rizzetto, M., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00010 · Cited by 2,836
Sarrazin, C., Kieffer, T. L., Bartels, D., Hanzelka, B., Müh, U., Welker, M., Wincheringer, D., Zhou, Y., Chu, H., Lin, C., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.037 · Cited by 616
Hirsch, M. S., Brun‐Vezinet, F., Clotet, B., Conway, B., Kuritzkes, D. R., D’Aquila, R. T., Demeter, L. M., Hammer, S. M., Johnson, V. A., Loveday, C., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/375597 · Cited by 514
Whole-Genome Sequence Assembly for Mammalian Genomes: Arachne 2
Jaffe, D. B., Butler, J., Gnerre, S., Mauceli, E., Lindblad-Toh, K., Mesirov, J. P., Zody, M. C., & Lander, E. S. (2003) · Genome Research · doi:10.1101/gr.828403 · Cited by 307
Bartels, D. J., Zhou, Y., Zhang, E. Z., Marcial, M., Byrn, R. A., Pfeiffer, T., Tigges, A. M., Adiwijaya, B. S., Lin, C., Kwong, A. D., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/591141 · Cited by 211
Sax, P. E., Islam, R., Walensky, R. P., Losina, E., Weinstein, M. C., Goldie, S. J., Sadownik, S. N., & Freedberg, K. A. (2005) · Clinical Infectious Diseases · doi:10.1086/496984 · Cited by 189
Young, K.-C., Lindsay, K. L., Lee, K.-J., Liu, W.-C., He, J.-W., Milstein, S. L., & Lai, M. M. C. (2003) · Hepatology · doi:10.1002/hep.1840380413 · Cited by 186
McCown, M. F., Rajyaguru, S., Le Pogam, S., Ali, S., Jiang, W.-R., Kang, H., Symons, J., Cammack, N., & Najera, I. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01317-07 · Cited by 164
Cited by
Domingo, E., Sheldon, J., & Perales, C. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05023-11 · Cited by 1,009
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Gane, E. J., Stedman, C. A., Hyland, R. H., Ding, X., Svarovskaia, E., Symonds, W. T., Hindes, R. G., & Berrey, M. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208953 · Cited by 764
Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
Sarrazin, C., & Zeuzem, S. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.11.055 · Cited by 504
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
Rong, L., Dahari, H., Ribeiro, R. M., & Perelson, A. S. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000544 · Cited by 355
Ten years of dengue drug discovery: Progress and prospects
Lim, S. P., Wang, Q.-Y., Noble, C. G., Chen, Y.-L., Dong, H., Zou, B., Yokokawa, F., Nilar, S., Smith, P., Beer, D., et al. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.013 · Cited by 350
Metadata
- Authors
- Kuntzen, T., Timm, J., Berical, A., Lennon, N., Berlin, A. M., Young, S. K., Lee, B., Heckerman, D., Carlson, J., Reyor, L. L., Kleyman, M., McMahon, C. M., Birch, C., Schulze zur Wiesch, J., Ledlie, T., Koehrsen, M., Kodira, C., Roberts, A. D., Lauer, G. M., Rosen, H. R., Bihl, F., Cerny, A., Spengler, U., Liu, Z., Kim, A. Y., Xing, Y., Schneidewind, A., Madey, M. A., Fleckenstein, J. F., Park, V. M., Galagan, J. E., Nusbaum, C., Walker, B. D., Lake-Bakaar, G. V., Daar, E. S., Jacobson, I. M., Gomperts, E. D., Edlin, B. R., Donfield, S. M., Chung, R. T., Talal, A. H., Marion, T., Birren, B. W., Henn, M. R., & Allen, T. M.
- Venue
- Hepatology
- Published
- 2008-12
- Volume
- 48
- Issue
- 6
- Pages
- 1769-1778
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2019523835
- Cited by
- 349
- References
- 20
- FWCI
- 26.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. https://app.cochat.ai/papers/10.1002/hep.22549
- The paper
- Kuntzen, T., Timm, J., Berical, A., Lennon, N., Berlin, A. M., Young, S. K., Lee, B., Heckerman, D., Carlson, J., Reyor, L. L., Kleyman, M., McMahon, C. M., Birch, C., Schulze zur Wiesch, J., Ledlie, T., Koehrsen, M., Kodira, C., Roberts, A. D., Lauer, G. M., . . . Allen, T. M. (2008). Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology. https://doi.org/10.1002/hep.22549
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.